💥 Dragon Pharma

ARA-290

✔️ Substance: pHBSP Peptide
✔️ Price For:Vial 16 mg
✔️ Brand: Dragon Pharma

Out of stock

Dragon Pharma ARA-290 16 mg

IDENTITYCompoundARA-290 (pHBSP Peptide)
BrandDragon Pharma
Strength16 mg
FormLyophilized Peptide Vial
ClassPeptide / Tissue Protective Compound

PEPTIDE PROFILEOriginHelix B Surface Peptide Analog
StructureNon-Erythropoietic EPO-Derived Peptide
Main TargetEPO Receptor / CD131 Complex
Primary RoleTissue Protection & Recovery Signaling
Research StatusExperimental Compound

PHARMACOLOGYMechanismTissue Protective Signaling
AdministrationSubcutaneous Injection (SC)
Blood EffectNo Classical Erythropoiesis
CategoryPeptide Research Compound
Clinical UseNot Approved Medication

SAFETY PROFILEHuman ApprovalNot Established
Immune ReactionPossible Peptide Response
Blood EffectsLower Than EPO Analogues
MonitoringHealth Parameters Recommended
PCTNot Required

STORAGE & PACKAGEBrandDragon Pharma
Package16 mg Multi-dose Vial
Storage2–8°C Refrigerated
ProtectionProtect From Light
FormLyophilized Powder

ADMINISTRATION PROFILERouteSubcutaneous (SC)
InjectionInsulin Syringe Recommended
ReconstitutionBacteriostatic Water
TimingConsistent Daily Schedule
CycleExperimental Research Duration

DOSING INFORMATIONResearch Dose1–2 mg/day
Weekly Amount7–14 mg/week
AdministrationDaily SC Injection
Typical Duration4–12 weeks
Usage TimeMorning or Recovery Period

USAGE PROFILEStart PhaseWeek 1
AdaptationWeeks 2–4
Research Window4–12 Weeks
GoalCellular Recovery Signaling
StoppingNo PCT Required

BODYBUILDING USAGERecoveryPost Training Support
Joint SupportTissue Protection Research
FatigueRecovery Signaling Interest
MuscleIndirect Recovery Benefits
Stack RoleRecovery Peptide

MECHANISM OF ACTIONReceptorEPO/CD131 Complex
SignalProtective Cellular Pathways
InflammationResearch Modulation
CellsProtection Signaling
GrowthNot Classical Anabolic Action

PHARMACOKINETICSReleasePeptide Activity Profile
MetabolismPeptide Degradation Pathways
Half-lifeVariable Research Data
ClearanceProteolytic Processing
ExposureDose Dependent

COMPATIBILITYRecovery StackRecovery Peptides
TrainingHigh Volume Programs
NutritionCalorie Controlled Phases
Anabolic CycleSupportive Research Role
PCTNot Applicable

CHEMICAL PROFILENameARA-290 / pHBSP
ClassEPO-Derived Peptide Analog
Formula Peptide Sequence Based Compound
Molecular DataResearch Dependent
CASNot Established

RECOVERY & DISCONTINUATION PCTNot Required
Hormonal ImpactNo Direct HPTA Suppression
StoppingGradual Discontinuation
RecoveryNatural Peptide Clearance
MonitoringGeneral Health Markers

CONTRAINDICATIONSPregnancyNot Recommended
AllergyPeptide Sensitivity
Medical ConditionsProfessional Assessment
Immune RiskMonitor Response
ResearchExperimental Compound

OVERVIEW

ARA-290 (pHBSP peptide) is an experimental tissue-protective peptide derived from the helix B surface region of erythropoietin. Unlike traditional erythropoietin compounds, ARA-290 was designed to activate protective signaling pathways without stimulating significant red blood cell production.

BENEFITS

Research interest in tissue protection
Potential recovery pathway support
Non-anabolic peptide mechanism
No direct androgenic activity
Cellular signaling research application
Potential inflammation pathway modulation
Recovery-focused peptide profile

POTENTIAL RISKS

Limited long-term human data
Possible injection reactions
Unknown effects from extended use
Experimental status
Individual peptide sensitivity
Quality differences between sources

PERFORMANCE PROFILE

Recovery Support

85%

Tissue Protection

82%

Inflammation Control

75%

Muscle Gain

20%

Hormonal Effect

10%

What is Dragon Pharma?

Dragon Pharma is a pharmaceutical brand commonly associated with performance-oriented research products, including peptides and sports pharmacology compounds. Product information should always be evaluated together with independent scientific literature, laboratory quality standards, and applicable regulations.

WHY CHOOSE Dragon Pharma

Dragon Pharma products are selected by some research communities because of brand recognition, standardized presentation, and availability of detailed product specifications. The quality assessment of any peptide product depends on manufacturing practices, analytical testing, storage conditions, and responsible handling.

For research compounds such as ARA-290, understanding the pharmacology of the substance remains more important than brand claims. Scientific evidence, purity verification, and appropriate storage are key factors when evaluating peptide products.

CONCLUSION

Dragon Pharma ARA-290 16 mg contains pHBSP peptide, an experimental EPO-derived compound investigated for tissue-protective signaling pathways. Unlike anabolic hormones, ARA-290 does not function through androgen receptors and is not designed as a direct muscle-building compound.

In bodybuilding and athletic research environments, ARA-290 is mainly discussed for its potential relationship with recovery processes, cellular protection, inflammation modulation, and tissue repair mechanisms. It is not classified as an anabolic agent and does not directly increase muscle protein synthesis like anabolic steroids.

For bodybuilding audiences, its primary interest is related to recovery-focused research, cellular protection, and potential support during demanding training periods. Current scientific understanding remains limited, and ARA-290 should be considered a research peptide rather than an established performance medication.

Responsible evaluation requires attention to scientific evidence, product quality, storage conditions, and individual health factors.

Disclaimer

This content is provided exclusively for educational and informational purposes. It does not constitute medical advice, treatment recommendations, or endorsement of experimental peptide use. ARA-290 is an investigational compound and is not an approved therapeutic medication in many jurisdictions.